廣告
香港股市 已收市

  • 恒指

    17,915.55
    -20.57 (-0.11%)
     

  • 國指

    6,368.10
    -5.38 (-0.08%)
     

  • 上證綜指

    3,030.25
    +14.36 (+0.48%)
     

  • 道指

    38,887.98
    +109.88 (+0.28%)
     

  • 標普 500

    5,483.73
    +10.50 (+0.19%)
     

  • 納指

    17,854.88
    -2.14 (-0.01%)
     

  • Vix指數

    12.62
    -0.13 (-1.02%)
     

  • 富時100

    8,185.49
    +43.34 (+0.53%)
     

  • 紐約期油

    80.53
    +0.20 (+0.25%)
     

  • 金價

    2,334.10
    +5.10 (+0.22%)
     

  • 美元

    7.8075
    -0.0026 (-0.03%)
     

  • 人民幣

    0.9288
    +0.0003 (+0.03%)
     

  • 日圓

    0.0492
    -0.0001 (-0.10%)
     

  • 歐元

    8.3811
    +0.0002 (+0.00%)
     

  • Bitcoin

    64,748.59
    -611.45 (-0.94%)
     

  • CMC Crypto 200

    1,348.33
    -41.07 (-2.95%)
     

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks Equity Research
·2 分鐘文章

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Why This 1 Growth Stock Should Be On Your Watchlist

Different than value or momentum investors, growth-oriented investors are concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, they'll want to focus on the Growth Style Score, which analyzes characteristics like projected and historical earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

廣告

Lantheus Holdings (LNTH)

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. It classifies its products into three categories — Precision Diagnostics (30.1% of FY23 revenues, up 9.4% from FY22), Radiopharmaceutical Oncology (65.9%, up 60.8%), and Strategic Partnerships and Other Revenue (4%, up 10.7%).

LNTH is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected to grow 14.1% year-over-year for the current fiscal year, with sales growth of 17.2%.

Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.54 to $7.11 per share. LNTH also boasts an average earnings surprise of 13.6%.

Looking at cash flow, Lantheus Holdings is expected to report cash flow growth of 41.9% this year; LNTH has generated cash flow growth of 54.5% over the past three to five years.

Investors should take the time to consider LNTH for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research